ArticleOsong public health and research perspectives2026
Personalized medicine as a novel therapeutic approach for autoimmune diseases: new insights and future prospects.
Article in Osong public health and research perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases are caused by dysfunction of the immune system, leading to inappropriate attacks on healthy tissues. Because patients have diverse genetic predispositions and heterogeneous responses to therapy, personalized medicine (PM) offers an opportunity to improve treatment effectiveness. PM uses diagnostic assessments to tailor treatment through individualized medical interventions. PM may improve therapeutic precision beyond traditional trial-and-error approaches, reduce adverse consequences, and improve outcomes by integrating genomic and transcriptomic data. PM considers genetic and molecular landscapes, immunologic factors, epigenetic influences, and environmental exposures to assess treatment response. However, challenges remain related to diagnostic access, the slow pace of biomarker identification, technological limitations, sustained patient engagement, data management, and computational requirements. Nevertheless, continued efforts to improve understanding of disease pathophysiology, gene expression, and immune regulation-together with the application of novel technologies and machine learning-may advance PM-based therapies. Additional opportunities include drug-target modeling and exploratory singlecell-based approaches to clarify patient-specific therapeutic mechanisms. This review briefly introduces the potential of PM for type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.